Drugmaker Novo Nordisk said on Jan. 28 that the U.S. Food and Drug Administration (FDA) had approved Ozempic for lowering the risk of kidney failure and disease progression in adults with Type 2 diabetes.
The semaglutide medication is also approved for reducing the risk of death from cardiovascular disease in patients with Type 2 diabetes and chronic kidney disease, according to Novo Nordisk’s statement.